Correction: Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang and Yi-Han Huang. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan. Journal of Clinical Medicine 2018, 7, 538

Lin, Jiun-Nong; Lai, Chung-Hsu; Yang, Chih-Hui; Huang, Yi-Han

doi:10.3390/jcm8040546

Open AccessCorrection

Correction: Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang and Yi-Han Huang. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan. Journal of Clinical Medicine 2018, 7, 538

by

Jiun-Nong Lin

^1,2,3,*

,

Chung-Hsu Lai

^1,2,

Chih-Hui Yang

⁴ and

Yi-Han Huang

¹

School of Medicine, College of Medicine, I-Shou University, Kaohsiung 824, Taiwan

²

Division of Infectious Diseases, Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung 824, Taiwan

³

Department of Critical Care Medicine, E-Da Hospital, I-Shou University, Kaohsiung 824, Taiwan

⁴

Department of Biological Science and Technology, Meiho University, Pingtung 912, Taiwan

^*

Author to whom correspondence should be addressed.

J. Clin. Med. 2019, 8(4), 546; https://doi.org/10.3390/jcm8040546

Submission received: 19 April 2019 / Accepted: 22 April 2019 / Published: 22 April 2019

Download Versions Notes

The authors wish to make the following corrections to this paper [1].

The authors have made a critical typing error and a counting error in Table 2 as the parameters of “Community-acquired infection” and “Healthcare-associated infection” were mistakenly switched with each other.

Accordingly, Table 2, which is shown as follows:

Table 2. Demographic characteristics, clinical information, and outcome of patients with E. meningoseptica and E. anophelis infections.

Characteristics	All (n = 92)	Number of Episodes (%)		OR (95% CI)	p-Value
Characteristics	All (n = 92)	E. meningoseptica (n = 20)	E. anophelis (n = 72)	OR (95% CI)	p-Value
Sex
Male	64 (69.6)	15 (75)	49 (68.1)	1.41 (0.46–4.35)	0.55
Female	28 (30.4)	5 (25)	23 (31.9)	0.71 (0.23–2.19)	0.55
Age
Range (year)	3–89	18–80	3–89
Median (year)	61	61	62.5
Mean ± standard deviation (year)	61.1 ± 17	56.6 ± 15.6	62.4 ± 17.3		0.179
Comorbidity
Diabetes mellitus	24 (26.1)	6 (30)	18 (25)	1.29 (0.43–3.84)	0.652
Hypertension	26 (28.3)	4 (20)	22 (30.6)	0.57 (0.17–1.9)	0.354
End-stage renal disease	5 (5.4)	1 (5)	4 (5.6)	0.9 (0.09–8.49)	0.999
Malignancy	40 (43.5)	8 (40)	32 (44.4)	0.83 (0.3-2.28)	0.723
Liver cirrhosis	8 (8.7)	3 (15)	5 (6.9)	2.37 (0.51–10.89)	0.365
Chronic obstructive pulmonary disease	9 (9.8)	0	9 (12.5)		0.197
Type of infection acquisition
Community-acquired infection	10 (10.9)	20	63 (87.5)		0.197
Healthcare-associated infection	82 (89.1)	0	9 (12.5)		0.197
Laboratory data
White blood cell count (cells/mm³)	13,281 ± 8740	13,353 ± 6687	13,261 ± 9271		0.967
Hemoglobin (g/dL)	10.1 ± 2.1	9.8 ± 2.4	10.1 ± 2.1		0.585
Platelet count (×1000 cells/mm³)	228,570 ± 131,056	216,550 ± 157,332	231,900 ± 123,846		0.69
Serum creatinine (mg/dL)	1.8 ± 1.7	1.6 ± 1.3	1.9 ± 1.8		0.584
Empirical antimicrobial therapy
β-lactams	41 (44.6)	11 (55)	30 (41.7)	1.71 (0.63–4.64)	0.289
β-lactam/lactamase inhibitors	20 (21.7)	4 (20)	16 (22.2)	0.88 (0.26–2.99)	0.999
Ciprofloxacin	10 (10.9)	1 (5)	9 (12.5)	0.37 (0.04–3.1)	0.685
Levofloxacin	24 (26.1)	1 (5)	23 (31.9)	0.11 (0.01–0.89)	0.015
Carbapenems	17 (18.5)	4 (20)	13 (18.1)	1.14 (0.33–3.96)	0.999
Aminoglycosides	9 (9.8)	3 (15)	6 (8.3)	1.94 (0.44–8.57)	0.402
Tigecycline	8 (8.7)	2 (10)	6 (8.3)	1.22 (0.23–6.58)	0.999
Colistin	6 (6.5)	1 (5)	5 (6.9)	0.71 (0.08–6.41)	0.999
Inappropriate empirical antimicrobial therapy	74 (80.4)	20 (100)	54 (75)		0.01
Shock	42 (45.7)	9 (45)	33 (45.8)	0.97 (0.36–2.62)	0.999
Admission to intensive care unit	44 (47.8)	9 (45)	35 (48.6)	0.87 (0.32–2.34)	0.775
Case fatality	25 (27.2)	6 (30)	19 (26.4)	1.2 (0.4–3.56)	0.748

Abbreviations: OR, odds ratio; CI, confidence interval.

should be replaced with the following:

Table 2. Demographic characteristics, clinical information, and outcome of patients with E. meningoseptica and E. anophelis infections.

Characteristics	All (n = 92)	Number of Episodes (%)		OR (95% CI)	p-Value
Characteristics	All (n = 92)	E. meningoseptica (n = 20)	E. anophelis (n = 72)	OR (95% CI)	p-Value
Sex
Male	64 (69.6)	15 (75)	49 (68.1)	1.41 (0.46–4.35)	0.55
Female	28 (30.4)	5 (25)	23 (31.9)	0.71 (0.23–2.19)	0.55
Age
Range (year)	3–89	18–80	3–89
Median (year)	61	61	62.5
Mean ± standard deviation (year)	61.1 ± 17	56.6 ± 15.6	62.4 ± 17.3		0.179
Comorbidity
Diabetes mellitus	24 (26.1)	6 (30)	18 (25)	1.29 (0.43–3.84)	0.652
Hypertension	26 (28.3)	4 (20)	22 (30.6)	0.57 (0.17–1.9)	0.354
End-stage renal disease	5 (5.4)	1 (5)	4 (5.6)	0.9 (0.09–8.49)	0.999
Malignancy	40 (43.5)	8 (40)	32 (44.4)	0.83 (0.3-2.28)	0.723
Liver cirrhosis	8 (8.7)	3 (15)	5 (6.9)	2.37 (0.51–10.89)	0.365
Chronic obstructive pulmonary disease	9 (9.8)	0	9 (12.5)		0.197
Type of infection acquisition
Community-acquired infection	9 (9.8)	0	9 (12.5)		0.197
Healthcare-associated infection	83 (90.2)	20	63 (87.5)		0.197
Laboratory data
White blood cell count (cells/mm³)	13,281 ± 8740	13,353 ± 6687	13,261 ± 9271		0.967
Hemoglobin (g/dL)	10.1 ± 2.1	9.8 ± 2.4	10.1 ± 2.1		0.585
Platelet count (×1000 cells/mm³)	228,570 ± 131,056	216,550 ± 157,332	231,900 ± 123,846		0.69
Serum creatinine (mg/dL)	1.8 ± 1.7	1.6 ± 1.3	1.9 ± 1.8		0.584
Empirical antimicrobial therapy
β-lactams	41 (44.6)	11 (55)	30 (41.7)	1.71 (0.63–4.64)	0.289
β-lactam/lactamase inhibitors	20 (21.7)	4 (20)	16 (22.2)	0.88 (0.26–2.99)	0.999
Ciprofloxacin	10 (10.9)	1 (5)	9 (12.5)	0.37 (0.04–3.1)	0.685
Levofloxacin	24 (26.1)	1 (5)	23 (31.9)	0.11 (0.01–0.89)	0.015
Carbapenems	17 (18.5)	4 (20)	13 (18.1)	1.14 (0.33–3.96)	0.999
Aminoglycosides	9 (9.8)	3 (15)	6 (8.3)	1.94 (0.44–8.57)	0.402
Tigecycline	8 (8.7)	2 (10)	6 (8.3)	1.22 (0.23–6.58)	0.999
Colistin	6 (6.5)	1 (5)	5 (6.9)	0.71 (0.08–6.41)	0.999
Inappropriate empirical antimicrobial therapy	74 (80.4)	20 (100)	54 (75)		0.01
Shock	42 (45.7)	9 (45)	33 (45.8)	0.97 (0.36–2.62)	0.999
Admission to intensive care unit	44 (47.8)	9 (45)	35 (48.6)	0.87 (0.32–2.34)	0.775
Case fatality	25 (27.2)	6 (30)	19 (26.4)	1.2 (0.4–3.56)	0.748

Abbreviations: OR, odds ratio; CI, confidence interval.

The authors apologize for any inconvenience caused to the readers by these changes.

Reference

Lin, J.-N.; Lai, C.-H.; Yang, C.-H.; Huang, Y.-H. Comparison of clinical manifestations, antimicrobial susceptibility patterns, and mutations of fluoroquinolone target genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis isolated in Taiwan. J. Clin. Med. 2018, 7, 538. [Google Scholar] [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Share and Cite

MDPI and ACS Style

Lin, J.-N.; Lai, C.-H.; Yang, C.-H.; Huang, Y.-H. Correction: Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang and Yi-Han Huang. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan. Journal of Clinical Medicine 2018, 7, 538. J. Clin. Med. 2019, 8, 546. https://doi.org/10.3390/jcm8040546

AMA Style

Lin J-N, Lai C-H, Yang C-H, Huang Y-H. Correction: Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang and Yi-Han Huang. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan. Journal of Clinical Medicine 2018, 7, 538. Journal of Clinical Medicine. 2019; 8(4):546. https://doi.org/10.3390/jcm8040546

Chicago/Turabian Style

Lin, Jiun-Nong, Chung-Hsu Lai, Chih-Hui Yang, and Yi-Han Huang. 2019. "Correction: Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang and Yi-Han Huang. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan. Journal of Clinical Medicine 2018, 7, 538" Journal of Clinical Medicine 8, no. 4: 546. https://doi.org/10.3390/jcm8040546

APA Style

Lin, J.-N., Lai, C.-H., Yang, C.-H., & Huang, Y.-H. (2019). Correction: Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang and Yi-Han Huang. Comparison of Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis Isolated in Taiwan. Journal of Clinical Medicine 2018, 7, 538. Journal of Clinical Medicine, 8(4), 546. https://doi.org/10.3390/jcm8040546

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Reference

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI